Innate Pharma (France)

company in Marseille, France

ISIN FR0010331421 LEI 9695002Y8420ZB8HJE29
Follow Innate Pharma (France) Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2024 EUR · IFRS
Revenue, last year €20.1M −67.4% vs prior year
Net income −€49.5M −553.5% vs prior year
EPS, diluted −€0.61 −577.8% vs prior year
Operating cash flow −€6.9M +78.8% vs prior year
Revenue by fiscal year
€85.8M
€70.5M
€24.7M
€57.7M
€61.6M
€20.1M
FY19 FY20 FY21 FY22 FY23 FY24

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−€100M−€50M€0€50M€100MFY19FY20FY21FY22FY23FY24
Show the numbers
YearRevenueNet income
FY24€20.1M−€49.5M
FY23€61.6M−€7.6M
FY22€57.7M−€58.1M
FY21€24.7M−€52.8M
FY20€70.5M−€64M
FY19€85.8M−€20.8M
MarginsShare of revenue
  • Operating margin
  • Net margin
−300%−200%−100%0%FY19FY20FY21FY22FY23FY24
Show the numbers
YearOperating marginNet margin
FY24−256.3%−245.9%
FY23−20.6%−12.3%
FY22−99.6%−100.7%
FY21−193.6%−213.8%
FY20−88.1%−90.8%
FY19−31.5%−24.2%
Free cash flowOperating cash flow minus capital expenditure
−€75M−€50M−€25M€0€25M€50MFY19FY20FY21FY22FY23FY24
Show the numbers
YearFree cash flow
FY24−€7.3M
FY23−€32.9M
FY22−€19.7M
FY21−€59.4M
FY20−€52.7M
FY19€33.7M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Innate Pharma (France)
  • Healthcare median
−300%−200%−100%0%FY19FY20FY21FY22FY23FY24
Show the numbers
YearInnate Pharma (France)Healthcare median
FY24−245.9%−47%
FY23−12.3%−58%
FY22−100.7%−80.4%
FY21−213.8%−71.9%
FY20−90.8%−62.2%
FY19−24.2%−46.3%